Study of the mechanisms involved in the vasorelaxation induced by (−)‐epigallocatechin‐3‐gallate in rat aorta
- 1 February 2006
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 147 (3) , 269-280
- https://doi.org/10.1038/sj.bjp.0706507
Abstract
This study investigated several mechanisms involved in the vasorelaxant effects of (−)‐epigallocatechin‐3‐gallate (EGCG). EGCG (1 μM–1 mM) concentration dependently relaxed, after a transient increase in tension, contractions induced by noradrenaline (NA, 1 μM), high extracellular KCl (60 mM), or phorbol 12‐myristate 13‐acetate (PMA, 1 μM) in intact rat aortic rings. In a Ca2+‐free solution, EGCG (1 μM–1 mM) relaxed 1 μMPMA‐induced contractions, without previous transient contraction. However, EGCG (1 μM–1 mM) did not affect the 1 μMokadaic acid‐induced contractions. Removal of endothelium and/or pretreatment with glibenclamide (10 μM), tetraethylammonium (2 mM) or charybdotoxin (100 nM) plus apamin (500 nM) did not modify the vasorelaxant effects of EGCG. In addition, EGCG noncompetitively antagonized the contractions induced by NA (in 1.5 mMCa2+‐containing solution) and Ca2+(in depolarizing Ca2+‐free high KCl 60 mMsolution). In rat aortic smooth muscle cells (RASMC), EGCG (100 μM) reduced increases in cytosolic free Ca2+concentration ([Ca2+]i) induced by angiotensin II (ANG II, 100 nM) and KCl (60 mM) in 1.5 mMCaCl2‐containing solution and by ANG II (100 nM) in the absence of extracellular Ca2+. In RASMC, EGCG (100 μM) did not modify basal generation of cAMP or cGMP, but significantly reversed the inhibitory effects of NA (1 μM) and high KCl (60 mM) on cAMP and cGMP production. EGCG inhibited the enzymatic activity of all the cyclic nucleotide PDE isoenzymes present in vascular tissue, being more effective on PDE2 (IC50∼17) and on PDE1 (IC50∼25). Our results suggest that the vasorelaxant effects of EGCG in rat aorta are mediated, at least in part, by an inhibition of PDE activity, and the subsequent increase in cyclic nucleotide levels in RASMC, which, in turn, can reduce agonist‐ or high KCl concentration‐induced increases in [Ca2+]i. British Journal of Pharmacology(2006)147, 269–280. doi:10.1038/sj.bjp.0706507Keywords
This publication has 57 references indexed in Scilit:
- The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cellsBiochemical and Biophysical Research Communications, 2004
- Molecular organization of bovine rod cGMP-phosphodiesterase 6Journal of Molecular Biology, 2001
- Study of the in vivo and in vitro cardiovascular effects of a hydralazine‐like vasodilator agent (HPS‐10) in normotensive ratsBritish Journal of Pharmacology, 1997
- Cyclic AMP and cyclic GMP relax phorbol ester-induced contractions of rat aorta by different mechanismsLife Sciences, 1997
- Inhibitory effect of nitrovasodilators and cyclic GMP on ET‐1‐activated Ca2+‐permeable nonselective cation channel in rat aortic smooth muscle cellsBritish Journal of Pharmacology, 1997
- Effects of flavonoids on rat aortic smooth muscle contractility: Structure-activity relationshipsGeneral Pharmacology: The Vascular System, 1996
- cAMP Signaling Inhibits Dihydropyridine-Sensitive Ca 2+ Influx in Vascular Smooth Muscle CellsHypertension, 1996
- Vasodilatory effects of flavonoids in rat aortic smooth muscle. Structure-activity relationshipsGeneral Pharmacology: The Vascular System, 1993
- Protein kinase C of smooth muscle.Hypertension, 1992
- Effects of E-1020, a new cyclic AMP-specific phosphodiesterase inhibitor, on cyclic amp and cytosolic free calcium of cultured vascular smooth muscle cells.Japanese Circulation Journal, 1990